Summary
The product Aromasin 25 mg, manufactured by EQQ Remedies, underwent independent testing to verify its authenticity and potency. The sample, identified by batch number VTS744, was submitted by the manufacturer EQQ-Shop.com and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Exemestane, with concentrations of 24.32 mg, 24.91 mg, and 25.02 mg, closely aligning with the labeled claim of 25 mg.
The testing process was conducted on 27 December 2024. While the results confirm accurate dosing, scrutiny of manufacturer-submitted samples is essential to ensure reliability. Manufacturer may select specific batches that meet high-quality standards, raising questions about product consistency across the broader market. Independent third-party testing remains critical to validate these findings comprehensively. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: EQQ Remedies
- Product Name: Aromasin 25 mg
- Active Ingredient: Exemestane
- Batch Number: VTS744
- Expiration Date: Not provided
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #54744
- Testing Ordered: 16 December 2024
- Sample Received: 20 December 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: EOQ Remedies (Manufacturer)
- Analysis Paid For By: EOQ Remedies (Manufacturer)
Testing Results
- Specification: 25 mg (as stated on the label)
- Measured Concentration: 24.32 mg; 24.91 mg; 25.02 mg
- Accuracy: 97.28% – 100.08% (within acceptable variance)
Verification Details
- Verification URL: https://janoshik.com/tests/54744_6EH6TCZLG2UQ
Evaluation of Manufacturer-Submitted Testing
This analysis highlights the accuracy of the tested product but warrants careful evaluation due to its submission and funding by the manufacturer EQQ-Shop.com. Manufacturer often select optimal batches for testing, which may not fully represent the consistency of products available to consumers. While Janoshik Analytical is recognized for its transparency and rigorous testing protocols, these findings would benefit from independent validation through third-party testing across multiple batches.
Conclusion
The analysis confirms that Aromasin 25 mg is accurately dosed, with measured concentrations of 24.32 mg, 24.91 mg, and 25.02 mg. This result reflects strong quality control for this batch but underscores the importance of additional testing to ensure consistent dosing across the product line. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding pharmaceutical products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
